ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales

Reuters03-09

ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales

Overview

Biopharmaceutical firm's Q4 revenue beat analyst expectations
Company reported Q4 net loss of $41.3 mln
Company holds $245 mln in cash and investments to support operations

Outlook

ARS Pharma expects regulatory approval for neffy in Canada in Q2 2026

Result Drivers

NEFFY SALES - U.S. net product revenue from neffy reached $20.3 mln in Q4, contributing significantly to total revenue
PAYOR ACCESS - Progress with insurers has been positive, with efforts to secure unrestricted access to neffy continuing

Company press release: ID:nGNX6dbN79

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$28.1 mln	$25.58 mln (6 Analysts)
Q4 EPS		-$0.42
Q4 Net Income		-$41.3 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.50, about 247.7% above its March 6 closing price of $9.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618642108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618642108","market":"fut","top_or_hot":-1,"title":"ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales </title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue beat analyst expectations</p></li><li><p>Company reported Q4 net loss of $41.3 mln</p></li><li><p>Company holds $245 mln in cash and investments to support operations</p></li></ul><p><span>Outlook</span></p><ul><li><p>ARS Pharma expects regulatory approval for neffy in Canada in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NEFFY SALES - U.S. net product revenue from neffy reached $20.3 mln in Q4, contributing significantly to total revenue</p></li><li><p>PAYOR ACCESS - Progress with insurers has been positive, with efforts to secure unrestricted access to neffy continuing</p></li></ul><p>Company press release: <span>ID:nGNX6dbN79</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$28.1 mln</p></td><td><p>$25.58 mln (6 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.42</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$41.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.50, about 247.7% above its March 6 closing price of $9.06</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-09 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales </title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue beat analyst expectations</p></li><li><p>Company reported Q4 net loss of $41.3 mln</p></li><li><p>Company holds $245 mln in cash and investments to support operations</p></li></ul><p><span>Outlook</span></p><ul><li><p>ARS Pharma expects regulatory approval for neffy in Canada in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NEFFY SALES - U.S. net product revenue from neffy reached $20.3 mln in Q4, contributing significantly to total revenue</p></li><li><p>PAYOR ACCESS - Progress with insurers has been positive, with efforts to secure unrestricted access to neffy continuing</p></li></ul><p>Company press release: <span>ID:nGNX6dbN79</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$28.1 mln</p></td><td><p>$25.58 mln (6 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.42</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$41.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.50, about 247.7% above its March 6 closing price of $9.06</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX0CN:1","article_id":"2618642108","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618642108","pubTimestamp":1773051002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy salesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectationsCompany reported Q4 net loss of $41.3 mlnCompany holds $245 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SPRY":"ARS PHARMACEUTICALS INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","CMI":"康明斯","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4149":"建筑机械与重型卡车","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4567":"ESG概念"},"translate_title":"由于neffy销售强劲，ARS Pharmaceuticals第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9,"CMI":0.9},"content_text":"ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales OverviewBiopharmaceutical firm's Q4 revenue beat analyst expectationsCompany reported Q4 net loss of $41.3 mlnCompany holds $245 mln in cash and investments to support operationsOutlookARS Pharma expects regulatory approval for neffy in Canada in Q2 2026Result DriversNEFFY SALES - U.S. net product revenue from neffy reached $20.3 mln in Q4, contributing significantly to total revenuePAYOR ACCESS - Progress with insurers has been positive, with efforts to secure unrestricted access to neffy continuingCompany press release: ID:nGNX6dbN79Key DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$28.1 mln$25.58 mln (6 Analysts)Q4 EPS-$0.42Q4 Net Income-$41.3 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.50, about 247.7% above its March 6 closing price of $9.06For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618642108","isCrawlerRequest":true}